Understand the source comparison
PT-141 vs Kisspeptin: Mechanism Comparison
Primary Receptor Target Melanocortin-4 receptor (MC4R) in hypothalamus KISS1R on GnRH neurons in arcuate nucleus PT-141 acts directly on CNS desire pathways; kisspeptin modulates upstream hormonal regulation Mechanism of Action Activates dopamine and norepinep
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Primary Receptor Target
- Melanocortin-4 receptor (MC4R) in hypothalamus
- KISS1R on GnRH neurons in arcuate nucleus
- PT-141 acts directly on CNS desire pathways; kisspeptin modulates upstream hormonal regulation
- Mechanism of Action
- Activates dopamine and norepinephrine pathways that increase sexual motivation independent of genital arousal
- Stimulates pulsatile GnRH release → LH secretion → gonadal steroidogenesis (testosterone/estradiol production)
- Different nodes in the sexual function cascade. PT-141 for immediate desire, kisspeptin for hormonal optimisation
- Time to Peak Effect
- 60–90 minutes post-subcutaneous injection
- LH surge within 15–30 minutes IV; testosterone changes require weeks of repeat dosing
- PT-141 is acutely timed; kisspeptin requires protocol continuity
- Half-Life
- 2.7 hours
- 28–32 minutes
- PT-141's longer half-life supports single pre-activity dosing; kisspeptin's rapid clearance limits acute utility
- Clinical Evidence Base
- FDA-approved for HSDD in premenopausal women (RECONNECT trials, n=1,267)
- Exploratory Phase I/II trials in male hypogonadism and reproductive endocrinology (n<200 total)
- PT-141 has regulatory approval and Phase III data; kisspeptin remains investigational